Mechanism of Action
NK3R Signaling and KNDy Neurons
NKB activates NK3R, a Gq-coupled GPCR expressed in hypothalamic KNDy neurons, prefrontal cortex, and peripheral sensory fibers. NK3R activation in KNDy neurons stimulates NKB auto-synaptic signaling that drives kisspeptin release, which in turn activates GnRH neurons to generate LH pulses. Dynorphin within the same KNDy neurons provides the inhibitory counter-signal that terminates each GnRH/LH pulse, creating the oscillatory reproductive axis.
Vasomotor Symptoms Mechanism
In premenopausal women, estrogen suppresses NKB expression in KNDy neurons through estrogen receptor alpha. After menopause, loss of estrogen disinhibits NKB, causing KNDy neuronal hypertrophy and NKB hypersignaling. NKB-activated KNDy neurons in the hypothalamus project to the thermoregulatory center, triggering inappropriate heat dissipation responses perceived as hot flashes. NK3R antagonism blocks this pathway without affecting estrogen receptors.
Research Summary
Hot Flashes / Vasomotor Symptoms
HumanThe SKYLIGHT Phase III trials of fezolinetant (NK3R antagonist) demonstrated 50-60% reduction in hot flash frequency and severity versus placebo in menopausal women. FDA approval in 2023 established fezolinetant as the first non-hormonal, non-antidepressant treatment specifically targeting the pathophysiology of vasomotor symptoms, directly validating the NKB/NK3R mechanism.
Reproductive Axis Regulation
HumanIV NKB infusion in women produces a dose-dependent, naloxone-reversible LH pulse, confirming NKB drives GnRH pulsatility through kisspeptin and opioid co-regulation. NK3R antagonism suppresses LH pulsatility, providing a novel approach to conditions of LH hypersecretion like PCOS.
PCOS Research
HumanWomen with PCOS have elevated NKB expression and increased LH pulse frequency driven by KNDy hypersignaling. NK3R antagonism (senktide challenge and antagonist trials) normalized LH pulsatility in PCOS patients in Phase II research, potentially reducing hyperandrogenemia and restoring ovulatory cyclicity.
Calculate your Neurokinin B dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| GnRH / LH pulse research | 4-8 nmol/kg | IV bolus, repeated q60-90 min | Intravenous |
| Reproductive physiology | 0.1-1 nmol/kg | Variable research protocol | IV (human) |
NKB itself is a research tool. Clinical applications use NK3R antagonists (fezolinetant for hot flashes; research agents for PCOS). Senktide is a selective NK3R agonist peptide used as a research probe.
Interactions
Safety Profile
IV NKB in human research studies is well tolerated at pharmacological doses. The most notable intended effect is LH pulse stimulation. NK3R antagonists (fezolinetant) in Phase III trials were well tolerated, with the main safety signals being liver enzyme elevations at higher doses (requiring monitoring) and no reproductive safety concerns at the approved dose. The non-hormonal mechanism avoids the cardiovascular and breast cancer risks associated with estrogen-based menopausal therapy.
References
- [1]Navarro VM, et al. Regulation of gonadotropin-releasing hormone secretion by kisspeptin/dynorphin/neurokinin B neurons in the arcuate nucleus of the ovariectomized sheep. Endocrinology. 2009.
- [2]Rance NE, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B, and dynorphin) neurons. Peptides. 2010.
- [3]Johnson KA, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1 and SKYLIGHT 2). Menopause. 2023.